专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009088414A3 ORAL PHARMACEUTICAL DOSAGE FORMS 审中-公开
公开(公告)号：WO2009088414A3
公开(公告)日：2009-07-16
申请号：PCT/US2008/013381
申请日：2008-12-05
申请人： DURECT CORPORATION , YUM, Su II
发明人： YUM, Su II , CHAO, Wendy , SU, Huey-Ching , FU, Roger , ZAMLOOT, Michael
IPC分类号： A01N43/42 , A61K9/64 , A61K31/44
摘要： Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.

2. 发明申请

WO2009051845A2 BIODEGRADABLE IMPLANTS WITH CONTROLLED BULK DENSITY 审中-公开
标题翻译：具有控制密度的生物可降解植入物
公开(公告)号：WO2009051845A2
公开(公告)日：2009-04-23
申请号：PCT/US2008/011967
申请日：2008-10-20
申请人： DURECT CORPORATION , YUM, Su, II , GOSKONDA, Sanjay , SU, Huey-Ching
发明人： YUM, Su, II , GOSKONDA, Sanjay , SU, Huey-Ching
IPC分类号： A61K9/00 , A61K38/09
CPC分类号： A61K9/0024 , A61K9/0004 , A61K38/09
摘要： Disclosed solid water permeable implants that include a water permeable polymer and an osmotically active drug formulation that comprises a drug; wherein the solid water permeable implant has a ratio R of bulk density of the solid water permeable implant to osmotic pressure of the drug formulation wherein R is greater than about 0.244 grams/milliliter-atm. Also disclosed are methods of making and using such solid water permeable implants.
摘要翻译：公开的固体水可渗透植入物，其包括水可渗透聚合物和包含药物的渗透活性药物制剂; 其中固体水可渗透植入物具有固体水可渗透植入物的体积密度与药物制剂的渗透压的比R，其中R大于约0.244克/毫升。还公开了制造和使用这种固体水可渗透植入物的方法。

3. 发明申请

WO2018026767A1 USE OF OXYGENATED CHOLESTEROL SULFATES (OCS) TO TREAT INFLAMMATORY SKIN DISEASE AND SKIN LESIONS 审中-公开
标题翻译：氧化胆固醇硫酸盐（OCS）治疗炎症性皮肤病和皮肤损伤
公开(公告)号：WO2018026767A1
公开(公告)日：2018-02-08
申请号：PCT/US2017/044821
申请日：2017-08-01
申请人： VIRGINIA COMMONWEALTH UNIVERSITY , DURECT CORPORATION
发明人： REN, Shunlin , LIN, WeiQi , BROWN, James E. , THEEUWES, Felix , KIM, Mee Jean , MIKSZTAL, Andrew R. , WU, Hongwei , LEE, Min L. , SU, Huey-Ching , TAMRAZ, Wilma
IPC分类号： A01N1/02 , A61K31/575
摘要： Methods of treating and prophylactically treating inflammatory skin diseases and skin lesions are provided. For instance, the methods may involve contacting the skin with an oxygenated cholesterol sulfate (OCS), e.g. 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or a pharmaceutically acceptable salt thereof.
摘要翻译：提供了治疗和预防性治疗炎症性皮肤病和皮肤损伤的方法。例如，所述方法可以包括使皮肤与含氧胆固醇硫酸盐（OCS）例如氧化胆固醇接触。 5-胆甾烯-3,25-二醇，3-硫酸盐（25H，3S）或其药学上可接受的盐。

4. 发明申请

WO2018009566A1 ORAL DOSAGE FORM WITH DRUG COMPOSITION, BARRIER LAYER AND DRUG LAYER 审中-公开
标题翻译：口服剂型与药物组合物，屏障层和药物层
公开(公告)号：WO2018009566A1
公开(公告)日：2018-01-11
申请号：PCT/US2017/040750
申请日：2017-07-05
申请人： DURECT CORPORATION
发明人： YUM, Su IL , CHAO, Wendy , SU, Huey-Ching , CHEN, Yen-Fei , CHIANG, Chin-Chih
IPC分类号： A61K9/48 , A61K9/52 , A61K9/56 , A61K47/14 , A61K31/4458 , A61K47/26 , A61K47/32 , A61K47/38
摘要： The present disclosure provides dosage forms designed to deliver active pharmaceutical ingredients (APIs) in a controlled release manner. For instance, the present disclosure includes dosage forms with adequate time of onset of action and reduced lag times in the fed state. Such dosage forms find use in a variety of conditions where a rapid onset of action is desired followed by an extended release phase for the active agent, for example in the treatment of ADHD, pain or anxiety. In some cases, the dosage form includes a drug composition including a pharmacologically active agent, a barrier layer covering at least a portion of the drug composition, and a drug layer covering at least a portion of the barrier layer, wherein the drug layer includes the pharmacologically active agent. Related methods of making and administering the disclosed dosage forms are also provided.
摘要翻译：本公开提供了设计成以控释方式递送活性药物成分（API）的剂型。例如，本公开包括具有足够的作用时间和在进食状态下减少的滞后时间的剂型。这种剂型可用于需要快速起效的各种病症，随后是活性剂的缓释阶段，例如用于治疗ADHD，疼痛或焦虑。在一些情况下，所述剂型包括药物组合物，所述药物组合物包含药理学活性剂，覆盖所述药物组合物的至少一部分的阻挡层以及覆盖所述阻挡层的至少一部分的药物层，其中所述药物层包含药理活性剂。还提供了制备和给药所公开的剂型的相关方法。

5. 发明申请

WO2014144975A1 COMPOSITIONS WITH A RHEOLOGICAL MODIFIER TO REDUCE DISSOLUTION VARIABILITY 审中-公开
标题翻译：具有降解溶解变异性的流变学改性剂的组合物
公开(公告)号：WO2014144975A1
公开(公告)日：2014-09-18
申请号：PCT/US2014/029607
申请日：2014-03-14
申请人： DURECT CORPORATION
发明人： YUM, Su Il , CHAO, Wendy , SU, Huey-Ching , FU, Roger , ZAMLOOT, Michael S. , BRATIN, Karl , SHANKER, Ravi M.
IPC分类号： A01N25/00
CPC分类号： A61K47/02 , A61K9/4816 , A61K9/485 , A61K31/485 , A61K47/14 , A61K47/26 , A61K47/38
摘要： The present disclosure provides compositions (e.g., extended release compositions) which exhibit a desirable pharmacokinetic profile of an active agent while providing reduced dissolution sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions are also provided.
摘要翻译：本公开提供了组合物（例如延长释放组合物），其表现出活性剂所需的药代动力学特征，同时提供降低的溶解样品变异性，例如以减少的胶囊间变异性和/或减少存储时间依赖性活性剂从组合物中平均释放的变化。还提供了制备和施用所公开的组合物的相关方法。

6. 发明申请

WO2014144984A1 COMPOSITIONS WITH THIXOTROPY AND ENHANCED DISSOLUTION REPRODUCIBILITY AND STABILITY 审中-公开
标题翻译：组合物与噻唑和增强的溶解可重复性和稳定性
公开(公告)号：WO2014144984A1
公开(公告)日：2014-09-18
申请号：PCT/US2014/029617
申请日：2014-03-14
申请人： DURECT CORPORATION
发明人： ZAMLOOT, Michael S. , FU, Roger , YUM, Su Il , CHAO, Wendy , SU, Huey-Ching
IPC分类号： C07D471/00
CPC分类号： A61K31/485 , A61K9/48 , A61K9/4816 , A61K9/485 , A61K9/4858 , A61K9/4866
摘要： The present disclosure provides extended release compositions including, formulations that comprise such compositions, which exhibit desirable dissolution of an active agent while maintaining its physical stability in a dosage form including, for example, providing reduced sample variability, e.g., in the form of reduced inter-capsule variability and/or a reduction in storage-time dependent change in mean release of the active agent from the composition. Related methods of making and administering the disclosed compositions and formulations are also provided.
摘要翻译：本公开内容提供了延长释放组合物，包括包含这样的组合物的制剂，其表现出活性剂的理想溶解，同时保持其剂型的物理稳定性，包括例如提供降低的样品变异性，例如以减少的间隔 - 胶囊变异性和/或活性剂从组合物的平均释放的储存时间依赖性变化的降低。还提供了制备和施用所公开的组合物和制剂的相关方法。

7. 发明申请

WO2012074883A1 BIODEGRADABLE DRUG DELIVERY COMPOSITION 审中-公开
标题翻译：可生物降解药物输送组合物
公开(公告)号：WO2012074883A1
公开(公告)日：2012-06-07
申请号：PCT/US2011/062139
申请日：2011-11-23
申请人： DURECT CORPORATION , VAN OSDOL, William W. , YUM, Su il , THEEUWES, Felix , SEKAR, Michael , GIBSON, John , BRANHAM, Keith , SU, Huey-Ching
发明人： VAN OSDOL, William W. , YUM, Su il , THEEUWES, Felix , SEKAR, Michael , GIBSON, John , BRANHAM, Keith , SU, Huey-Ching
IPC分类号： A61K38/08
CPC分类号： A61K47/48246 , A61K9/0019 , A61K31/7052 , A61K38/212 , A61K38/26 , A61K38/27 , A61K47/14 , A61K47/26 , A61K47/34 , A61K47/52 , A61K47/541 , A61K47/64
摘要： The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.
摘要翻译：本公开提供了包含载体和包含分散在载体中的有益剂的不溶性组分的可生物降解的药物递送组合物。通常，组合物不是乳液，而是具有低粘度，并且进一步提供有益剂随时间的最小化初始爆发和持续释放。还提供了包括可生物降解的药物递送组合物或其组分的试剂盒，以及制备和使用可生物降解的药物递送组合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式